Karyopharm Therapeutics (KPTI) PT Raised to $19 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'
March 15, 2018 2:01 PM EDTBaird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Recent progress across the selinexor franchise was highlighted, and management indicated initial commercial preparations are underway, a positive sign, in... More
Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 15c
March 15, 2018 7:01 AM EDTNote: EPS may not be comparable
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.80), $0.15 worse than the analyst estimate of ($0.65).
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing cash, cash equivalents and investments will be sufficient to fund its... More
